
- /
- Supported exchanges
- / US
- / PEPG.NASDAQ
PepGen Ltd (PEPG NASDAQ) stock market data APIs
PepGen Ltd Financial Data Overview
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. Its lead product candidates comprise PGN-EDO51, an EDO peptide which is Phase 2 clinical trial to treat duchenne muscular dystrophy (DMD) patients that are amenable to an exon 51-skipping approach; PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and PGN-EDO53, which is in preclinical trial to treat duchenne muscular dystrophy. The company was founded in 2018 and is based in Boston, Massachusetts.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with PepGen Ltd (top by weight)
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get PepGen Ltd data using free add-ons & libraries
Get PepGen Ltd Fundamental Data
PepGen Ltd Fundamental data includes:
- Net Revenue:
- EBITDA: -101 288 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-07
- EPS/Forecast: -0.81
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
PepGen Ltd News

MODD, GALT, XCUR, PEPG, BSGM Stocks Pop After Hours On Clinical Updates And Strategic Moves
(RTTNews) - Several biotech stocks made sharp moves in after-hours trading on Thursday, September 11, 2025, driven by clinical updates, strategic pivots, and rebranding efforts. Here's a quick look at...


After-Hours Biotech Gainers: Insider Buys, Trial Updates, And Strategic Deals Fuel Momentum
(RTTNews) - Biotech stocks are showing renewed momentum, with several small-cap names posting notable after-hours gains and attracting investor attention. From insider buying and strategic partnership...

Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of PepGen Inc.(PEPG) Shareholders
NEW YORK, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in PepGen Inc. ("PepGen Inc." or the "Company") (NASDAQ: PEPG) of a class action securities lawsuit. CLASS DEFIN...

PEPGEN (PEPG) FINAL DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds PepGen Investors of the August 8th Deadline and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. Litigation Attorneys Encourage Investors Who Suffered Losses In PepGen (PEPG) To Contact Them Directly To Discuss Their Options If you purchased or acquired securities in ...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.